ライフサイエンスコーパス: exhale

1 ]) but not with forced expiratory flow after exhaling 75% of FVC or asthma.

2 C) ratio, and forced expiratory volume after exhaling 75% of vital capacity (FEF75), whereas those bo

3 ed by highly transmissible influenza viruses exhale a greater number of aerosol particles and more in

4 with a 0.12-L decrease in the lung volume of exhaled air (95% confidence interval, -0.17 to -0.07; P

5 fractional concentration of nitric oxide in exhaled air (FeNO) was measured.

6 parallel changes in CH4 concentration in the exhaled air (Pearson's r = 0.669 or r = 0.632, respectiv

7 frequency of breathing and peak flow rate of exhaled air are necessary parameters to detect chronic o

8 loxanes (D4 and D5) can be quantified in end-exhaled air at concentrations as low as background level

9 s developed for analysis of D4 and D5 in end-exhaled air by thermal desorption gas chromatography mas

10 Smoking status was biochemically verified (exhaled air CO and serum cotinine).

11 el successful reproduced observed chloroform exhaled air concentrations resulting from an inhalation

12 The limit of quantification was 2.1 ng/L end-exhaled air for D4 and 1.4 ng/L end-exhaled air for D5.

13 ng/L end-exhaled air for D4 and 1.4 ng/L end-exhaled air for D5.

14 Fifteen consumers provided end-exhaled air samples that were collected using Bio-VOC br

15 e back of the oral cavity are transported by exhaled air through the nasal cavity to stimulate the ol

16 outhpiece of optimal length ensured that the exhaled air was focused on the humidity-sensor.

17 lso measured the fraction of nitric oxide in exhaled air, blood and sputum eosinophils, and airway hy

18 ires, measurement of exhaled nitric oxide in exhaled air, blood sampling for inflammatory biomarkers,

19 ats to test the appearance of the gas in the exhaled air.

20 = -2.37 +/- 0.57 per mille (SD)), and human exhaled breath (EB; deltaD = -119.63 +/- 7.27 per mille

21 itor (PAI-1), and factor XIII (FXIII), NO in exhaled breath (FENO ), spirometry (FEV1 ) and eosinophi

22 In this study, we profiled the exhaled breath (~450 mL) volatile organic compounds (VOC

23 carbon dioxide (CO(2)), a major component of exhaled breath [1, 2]; heat elevated above ambient tempe

24 The present study assessed whether exhaled breath analysis using Selected Ion Flow Tube Mas

25 osis of human echinococcosis disease through exhaled breath analysis, suitable for early diagnosis an

26 from a variety of sources, including airway, exhaled breath and blood.

27 ruses, influenza viruses and rhinoviruses in exhaled breath and coughs of children and adults with ac

28 sured carbon monoxide (CO) concentrations in exhaled breath and personal air to assess exposure.

29 electrospray ionization mass spectrometry of exhaled breath and UHPLC-HRMS/MS experiments using exhal

30 Molecular fingerprints of exhaled breath are associated with inflammation and can

31 CO in exhaled breath at the same time as spirometry was associ

32 successfully applied to analyze PCs in human exhaled breath by using a simple and convenient collecti

33 y aimed to apply the metabolomic approach to exhaled breath condensate (breathomics) to discriminate

34 Collection of exhaled breath condensate (EBC) and quantification of bi

35 We sought to investigate whether exhaled breath condensate (EBC) lipoxin and leukotriene

36 Exhaled breath condensate (EBC) metabolite profiles also

37 rlaps the generally accepted H2O2 content in exhaled breath condensate (EBC), with the sensitivity of

38 ecrease in plasma MCP-1 on day 3 and reduced exhaled breath condensate acidification.

39 mentation of early screening methods such as exhaled breath condensate analysis and low dose computed

40 Biomarkers in exhaled breath condensate and airway resistance (pre- an

41 ether volatile organic compounds measured in exhaled breath condensate can be used as biomarkers for

42 Samples tested with this approach include exhaled breath condensate collected from cystic fibrosis

43 15-epi-lipoxin-A4 was identified in exhaled breath condensate from LAM subjects and was incr

44 e aimed at verifying whether metabolomics of exhaled breath condensate from obese asthmatic (OA) pati

45 e aimed at verifying whether metabolomics of exhaled breath condensate from obese asthmatic (OA) pati

46 The exhaled breath condensate hydrogen peroxide concentratio

47 nvestigation of using this system to measure exhaled breath condensate hydrogen peroxide for monitori

48 We evaluated exhaled breath condensate hydrogen peroxide in 60 patien

49 newly developed assay and device to measure exhaled breath condensate hydrogen peroxide in asthma pa

50 evice for measuring hydrogen peroxide in the exhaled breath condensate of asthma patients and healthy

51 enals), biomarkers of lipid peroxidation, in exhaled breath condensate of three healthy subjects (N =

52 y fractional exhaled nitric oxide (FeNO) and exhaled breath condensate pH and nitrogen oxides (NOx).

53 d oxidative stress (exhaled nitric oxide and exhaled breath condensate pH, malondialdehyde, and nitri

54 essed by plasma cytokines and intraoperative exhaled breath condensate pH; alveolar type 1 epithelial

55 tion, benzothiazoles were also determined in exhaled breath condensate samples by means of ultra high

56 Exhaled breath condensate samples were collected, and br

57 Analysis of the exhaled breath condensate volatilome allowed the distinc

58 Biomarkers in exhaled breath condensate, exhaled volatile organic comp

59 d breath and UHPLC-HRMS/MS experiments using exhaled breath condensate, respectively.

60 Exhaled breath contains thousands of volatile organic co

61 the noninvasive detection of metabolites in exhaled breath could potentially help to address this pr

62 ance was successfully studied and applied in exhaled breath detection.

63 Rationale: Analysis of exhaled breath for asthma phenotyping using endogenously

64 These included nasal wash fluid and exhaled breath for PCR-based detection of viral RNA, lun

65 Exhaled breath from 14 rats was repeatedly sampled by e-

66 hy-mass spectrometry (GC-MS) analysis of the exhaled breath from three rats.

67 Biomarkers from exhaled breath include fractional exhaled nitric oxide,

68 atio determination of (12)CO2 and (13)CO2 in exhaled breath is of critical importance in the field of

69 ory symptoms) and spirometry and CO (ppm) in exhaled breath measurements.

70 We describe the analysis workflow to profile exhaled breath metabolites and provide here a first libr

71 rger studies to elucidate the association of exhaled breath metabolites with gender-specific disease

72 rformed to test for associations between the exhaled breath metabolome and sonographic lung abnormali

73 weight, lung function, respiratory symptoms, exhaled breath nitric oxide [eNO], exhaled carbon monoxi

74 traits, including respiratory parameters and exhaled breath nitric oxide.

75 enabled us to document baseline compounds in exhaled breath of healthy animals and to study changes i

76 is rapid with maximal detection of (15)N2 in exhaled breath of infected rabbits within 5-10 min.

77 tions of acetonitrile have been found in the exhaled breath of patients with cystic fibrosis1 and may

78 rk shows evidence for real-time detection in exhaled breath of the complete series of saturated linea

79 On-line analysis of exhaled breath offers insight into a person's metabolism

80 ore straightforward than those measured from exhaled breath or directly from the airway.

81 of four phosphatidylcholines (PCs) in human exhaled breath particles.

82 Exhaled breath profiles were measured by using either an

83 Exhaled breath samples were analyzed from 81 patients wi

84 a and identify recognized pathogens of SRKW, exhaled breath samples were collected between 2006-2009

85 Exhaled breath samples were collected using 2-L double-l

86 In this longitudinal multicenter study exhaled breath samples were taken from an unselected sub

87 to Mycobacterium tuberculosis antigen in the exhaled breath samples, obtained from healthy subjects a

88 of volatile organic compounds (VOCs) within exhaled breath samples.

89 tion of volatile organic compounds (VOCs) in exhaled breath samples.

90 ectable by high through-output techniques in exhaled breath showing a specific pattern of VOCs.

91 ent as well, suitable for acetone sensing in exhaled breath that clearly distinguishes between health

92 Objectives: To determine whether analysis of exhaled breath using endogenously generated VOCs can be

93 Distinct exhaled breath VOC profiles can distinguish patients wit

94 Eleven exhaled breath VOCs were identified from both uni and mu

95 Recently, the presence of these gases in exhaled breath was also correlated with obesity.

96 The highest amount in exhaled breath was found for DPPC with median concentrat

97 olatile organic compounds in ambient air and exhaled breath with applications ranging from environmen

98 extraction platforms, kraft paper mills, and exhaled breath, but its determination at ppb levels rema

99 r can be utilized for untargeted analysis of exhaled breath, with the capability to identify hitherto

100 ic inflammation in humans and is released in exhaled breath.

101 kers (even at p.p.b. levels) in highly humid exhaled breath.

102 humid gaseous media such as ambient air and exhaled breath.

103 or the full omega-oxidation pathway in human exhaled breath.

104 able for the identification of biomarkers in exhaled breath.

105 he detection of benzothiazole derivatives in exhaled breath.

106 he quantification of acetone and isoprene in exhaled breath.

107 diseases and for molecular fingerprinting of exhaled breath.

108 usly to study their relation with acetone in exhaled breath.

109 refore interest in detecting acetonitrile in exhaled breath.

110 latile and nonvolatile compounds in cetacean exhaled breath.

111 n be detected by e-Nose data analysis of the exhaled breath.

112 been chosen for monitoring trace acetone in exhaled breath.

113 itial fluid, blood, wound exudate as well as exhaled breath.

114 doluminal-gas biopsies and noninvasive mixed-exhaled-breath testing for esophagogastric-cancer detect

115 d peripheral airways and compare it with the exhaled bronchial and alveolar NO levels in patients wit

116 om occupancy detection based on CO(2) levels exhaled by humans.

117 n-cabin UFPs by approximately 90%, passenger-exhaled carbon dioxide (CO2) can quickly accumulate insi

118 ey model of tuberculosis transmission, using exhaled carbon dioxide as a tracer gas, to describe tran

119 ial cues available to guide such navigation: exhaled carbon dioxide, a plethora of skin odors, the ho

120 Exhaled carbon monoxide (COex) level has been proposed a

121 symptoms, exhaled breath nitric oxide [eNO], exhaled carbon monoxide [eCO], and high-resolution compu

122 or more days of continuous abstinence and an exhaled carbon monoxide level of 3 ppm or less.

123 lf-reported smoking or if their preoperative exhaled carbon monoxide level was 10 ppm or higher.

124 Preoperative exhaled carbon monoxide level was not associated with th

125 Smoking status and preoperative exhaled carbon monoxide level, assessed by nurses in the

126 gery and SSI was not related to preoperative exhaled carbon monoxide levels.

127 abstinence was established and confirmed by exhaled carbon monoxide measurements at TQD and at inter

128 The primary end point was the 4-week exhaled carbon monoxide-confirmed continuous abstinence

129 f the relapse-prevention phase, confirmed by exhaled carbon monoxide.

130 at appendectomy is associated with decreased exhaled CH(4).

131 k between splanchnic circulatory changes and exhaled CH4 in an attempt to recognize intestinal perfus

132 The concentration of exhaled CH4 was measured online simultaneously with high

133 sociated negatively with microbial richness, exhaled CH4, presence of methanogens, and enterotypes en

134 ( P<0.001), despite comparable increases in exhaled CO (24+/-1 versus 28+/-3 ppm, hookah versus CO).

135 similarly with all types of smoking, whereas exhaled CO increased 9- to 10-fold more after charcoal-h

136 Only participants who provided an exhaled CO measurement or self-reported their smoking st

137 Exhaled CO(2) is an important host-seeking cue for Anoph

138 rs, mean+/-SE), we measured plasma nicotine, exhaled CO, and brachial artery flow-mediated dilation (

139 ct influence on ventilation, oxygenation and exhaled CO2.

140 Exhaled concentrations of 45 volatile organic compounds

141 perimental data on a close association of an exhaled endogenous gas with acute mesenteric macro- and

142 re reduction and NO formation as measured by exhaled gas concentration from inhaled sodium nitrite we

143 ic compounds or host response markers in the exhaled gas could give an earlier diagnosis of ventilato

144 To induce changes in the composition of exhaled gas we induced ventilator-associated pneumonia v

145 he volatile organic compound patterns in the exhaled gas were compared and correlated with ventilator

146 s differentiation by noninvasive analyses of exhaled gas.

147 oninvasive, rapid, and sensitive analysis of exhaled gas.

148 2) bacterial species-specific changes in the exhaled gas.

149 For each subject, we measured exhaled H2 and CH4, oro-anal transit time, and the sever

150 bjects; however, limited studies focusing on exhaled human breath are available in the literature.

151 The identification of chemical compounds in exhaled human breath is promising in the search for new

152 t-of-care diagnosis of metabolic diseases in exhaled human breath.

153 s demonstrated with the analysis of 27 nL of exhaled human breath.

154 ased sensor prototype for CO(2) detection in exhaled human breath.

155 Concentrations of exhaled hydrogen ions, nitric oxide products, hydrogen p

156 The acetone concentration exhaled in the breath of three type 1 diabetes patients

157 re susceptible to spider-attack because they exhaled less nicotine because of lower hemolymph nicotin

158 osis patients presented increased plasma and exhaled markers of the NO pathway while their FMD signif

159 l scaling laws for the transport distance of exhaled material including 1) transport over a short dis

160 Exhaled metabolites were analyzed centrally by using an

161 ) to identify severe asthma phenotypes using exhaled metabolomic fingerprints obtained from a composi

162 rgone appendectomies had decreased levels of exhaled methane (CH(4)).

163 We have identified and followed up exhaled molecular phenotypes of severe asthma, which wer

164 , 1.1-2.3); being overweight (1.5, 1.0-2.3); exhaled nitric oxide >/= 20 ppb (1.9, 1.3-2.7); and tota

165 ere analysed post hoc by baseline fractional exhaled nitric oxide (<35 and >=35 ppb) and blood eosino

166 Despite lower fraction of exhaled nitric oxide (30.0 vs 62.6 ppb; P = .037) and re

167 Exhaled nitric oxide (eNO) is a biomarker of airway infl

168 Exhaled nitric oxide (eNO), induced sputum cell counts,

169 The fractional exhaled nitric oxide (F(E) NO) is a marker for type 2 in

170 ients underwent VOC measurement, fraction of exhaled nitric oxide (Fe(NO)) spirometry, sputum inducti

171 Suppression of fractional exhaled nitric oxide (Fe(NO)) with directly observed ICS

172 Fractional exhaled nitric oxide (FENO ) was measured.

173 rway inflammation was assessed by fractional exhaled nitric oxide (FeNO) and exhaled breath condensat

174 sensitization, allergic rhinitis, fractional exhaled nitric oxide (FeNO) and lung function.

175 of airway inflammation including fractional exhaled nitric oxide (FeNO) and sputum eosinophils would

176 the association between baseline fractional exhaled nitric oxide (FeNO) and the response to inhaled

177 relation to the asthma biomarker fractional exhaled nitric oxide (FeNO) in 155 subjects with asthma

178 ral corticosteroid adherence, and fractional exhaled nitric oxide (FeNO) in 17 studies for inhaled co

179 microarray technique (BioIC) and fraction of exhaled nitric oxide (FeNO) in a population sample of 13

180 Fraction of exhaled nitric oxide (FeNO) is a marker of eosinophilic

181 The fraction of exhaled nitric oxide (FENO) is a useful marker of asthma

182 On the other hands, the fraction of exhaled nitric oxide (FENO) is a useful noninvasive mark

183 e have previously described that fraction of exhaled nitric oxide (Feno) levels and blood eosinophil

184 nts undergoing airway challenge, fraction of exhaled nitric oxide (FENO) levels decrease after bronch

185 The significance of fractional exhaled nitric oxide (Feno) levels in children with sick

186 nophil counts, total IgE levels, fraction of exhaled nitric oxide (Feno) levels, or FEV1 percent pred

187 The added value of fractional exhaled nitric oxide (Feno) remains controversial in the

188 The fraction of exhaled nitric oxide (Feno) value is a biomarker of eosi

189 wheeze and asthma and increased fraction of exhaled nitric oxide (Feno) values in children.

190 The increased fraction of exhaled nitric oxide (Feno) values observed in asthmatic

191 y accessible biomarkers included fraction of exhaled nitric oxide (Feno) values, blood eosinophil (bE

192 en August 2013 and February 2015, fractional exhaled nitric oxide (FeNO) was measured from 112 partic

193 ween 25% and 75% [FEF25-75]) and fraction of exhaled nitric oxide (Feno) were made at 14 to 15 years

194 cohort, we assessed whether the fraction of exhaled nitric oxide (FeNO), a biomarker of airway infla

195 Biomarkers, such as the fraction of exhaled nitric oxide (Feno), allow further tailoring of

196 ction, bronchial responsiveness, fraction of exhaled nitric oxide (Feno), and allergic sensitization.

197 th respiratory resistance (Rint), fractional exhaled nitric oxide (Feno), and risks of wheezing and a

198 airway inflammation, assessed by fraction of exhaled nitric oxide (FeNO), in a population-based study

199 at 18 years of age, with normal fraction of exhaled nitric oxide (Feno), low bronchial hyperresponsi

200 Repeated measures of exhaled nitric oxide (FeNO), lung function (FEV1, FVC),

201 Results of spirometry, fractional exhaled nitric oxide (Feno), mannitol provocation testin

202 ionnaire, spirometry, skin prick test (SPT), exhaled nitric oxide (FeNO), smell test, and peak nasal

203 nction tests, and measurement of fraction of exhaled nitric oxide (FeNO).

204 nflammation was measured daily as fractional exhaled nitric oxide (FeNO).

205 and induced sputum collection and fractional exhaled nitric oxide (FeNO).

206 ometry, methacholine and mannitol challenge, exhaled nitric oxide (FeNO); Asthma Control Questionnair

207 INTRODUCTION: Increased exhaled nitric oxide (NO) levels in asthma are suggested

208 Increased exhaled nitric oxide (NO) levels in asthma are suggested

209 ith aspirin-exacerbated respiratory disease, exhaled nitric oxide (P < 0.05), plasma tryptase (P < 0.

210 ion, including blood eosinophils (P = .001), exhaled nitric oxide (P = .003), and epithelial CLCA1 (P

211 ones, 3.0 [95% CI, 2.4-3.7]), and changes in exhaled nitric oxide (placebo, -3.48 ppb [95% CI, -5.99

212 nchodilator reversibility >/=12%, fractional exhaled nitric oxide [FeNO] >/=35 parts per billion, and

213 nophils >=150/300 cells/uL and/or fractional exhaled nitric oxide [FeNO] >=25 ppb), annualized severe

214 of inflammatory biomarkers (ie, fraction of exhaled nitric oxide [Feno], sputum eosinophil count, an

215 Allergen-induced levels of fractional exhaled nitric oxide and airway hyperresponsiveness to m

216 ere observed in the high baseline fractional exhaled nitric oxide and blood eosinophil subgroups (207

217 -223, 550] for the high baseline fractional exhaled nitric oxide and blood eosinophil subgroups, res

218 pulmonary inflammation and oxidative stress (exhaled nitric oxide and exhaled breath condensate pH, m

219 differences in sputum neutrophil counts and exhaled nitric oxide and serum IgE levels.

220 , RV, TLC, DLCO, and KCO) and measurement of exhaled nitric oxide before HSCT and 3, 6, and 12 months

221 l, -1.40 to -0.77]) and had lower fractional exhaled nitric oxide concentrations (13.9 vs. 24.4 ppb;

222 O(2) levels and lung function and fractional exhaled nitric oxide did not differ by BMI category.

223 eline bronchodilator response and fractional exhaled nitric oxide had good sensitivity and specificit

224 rticulate oxidative burden as a predictor of exhaled nitric oxide in children with asthma.

225 ocol included questionnaires, measurement of exhaled nitric oxide in exhaled air, blood sampling for

226 d value or >/=15% increase), (3) fraction of exhaled nitric oxide levels (<24 ppb), and (4) sputum eo

227 onchodilator response (P = 0.03), and higher exhaled nitric oxide levels (P = 0.04) compared with the

228 ncrease in sputum eosinophils and fractional exhaled nitric oxide levels affected by treatment.

229 Fractional exhaled nitric oxide levels were higher in men than wome

230 Induced sputum cells and fractional exhaled nitric oxide levels were used to assess airway i

231 iomarkers sputum eosinophilia and fractional exhaled nitric oxide levels, along with oral corticoster

232 rgest cluster, had normal lung function, low exhaled nitric oxide levels, and lower inhaled steroid r

233 Spirometry, lung volumes, exhaled nitric oxide levels, and systemic biomarker leve

234 osal eosinophils, as well as high fractional exhaled nitric oxide levels, exacerbation rates, and ora

235 bronchodilator responsiveness and fractional exhaled nitric oxide levels.

236 ng significantly correlated with fraction of exhaled nitric oxide levels.

237 aires, atopy and pulmonary function testing, exhaled nitric oxide measurement, and blood collection.

238 n response, 28 (52%) of 54 had a fraction of exhaled nitric oxide response, and 29 (54%) of 54 had a

239 Fractional exhaled nitric oxide testing is recommended to assist in

240 sputum eosinophils) or baseline fraction of exhaled nitric oxide to stratify patients by eosinophili

241 points for IgE levels (268 IU), fraction of exhaled nitric oxide values (14.5 ppb), and blood eosino

242 x and rhinitis, bronchial reversibility, and exhaled nitric oxide values (all P < 0.05).

243 nificantly greater than those for fractional exhaled nitric oxide values and sputum eosinophil counts

244 ls, blood eosinophil counts, and fraction of exhaled nitric oxide values in relationship to sputum eo

245 cts performed spirometry and had fraction of exhaled nitric oxide values measured twice during the sc

246 erresponsiveness to mannitol and fraction of exhaled nitric oxide values were measured.

247 ct sequence variants and FEV(1), fraction of exhaled nitric oxide values, BAL fluid cell counts, and

248 factors, allergic sensitization, fraction of exhaled nitric oxide values, spirometric measurements, a

249 Fractional exhaled nitric oxide was validly measured in 3881 health

250 Levels of fractional exhaled nitric oxide were also measured.

251 tors for allergic rhinitis were 25% for high exhaled nitric oxide, 22% for allergic sensitization to

252 and important risk factors include elevated exhaled nitric oxide, allergic sensitization to common h

253 Children also underwent spirometry, exhaled nitric oxide, allergy skin testing to 10 common

254 impulse oscillometry, alveolar and bronchial exhaled nitric oxide, and a methacholine provocation.

255 clinical outcome measures (FEV1, fraction of exhaled nitric oxide, and blood eosinophils) were assess

256 pes of asthma by using blood, bronchoscopic, exhaled nitric oxide, and clinical data from the Severe

257 cs such as atopy, lung function, fraction of exhaled nitric oxide, and medication use were calculated

258 uiet natural sleep included tidal breathing, exhaled nitric oxide, and multiple breath washout measur

259 nation of blood eosinophil count, fractional exhaled nitric oxide, Asthma Control Questionnaire, medi

260 ge, body mass index, FEV1, PC20, fraction of exhaled nitric oxide, blood eosinophil counts, and inhal

261 ent (95% CI, -32.9%, -10.2%), and fractional exhaled nitric oxide, CCL26 and SERPINB2 mRNA expression

262 Skin prick testing, lung function tests, exhaled nitric oxide, hematimetry, and total serum IgE w

263 rkers from exhaled breath include fractional exhaled nitric oxide, measurement of which can help iden

264 b did not affect FEV(1), FVC, and fractional exhaled nitric oxide, neither at baseline nor after RV16

265 els with percent predicted FEV1, fraction of exhaled nitric oxide, or asthma symptoms.

266 2 airway inflammation, including fractional exhaled nitric oxide, serum IgE, periostin, and blood an

267 FEV(1), FVC, fractional exhaled nitric oxide, symptom scores (asthma control sco

268 er clinical biomarkers for asthma, including exhaled nitric oxide, total serum IgE and pulmonary func

269 randomisation groups in FEV1 or fraction of exhaled nitric oxide.

270 he allergen challenge and in the fraction of exhaled nitric oxide.

271 tests, spirometry with bronchodilation, and exhaled nitric oxide.

272 Exhaled NO (FeNO) is a marker of inflammation in asthma

273 asthma severity or by levels of fraction of exhaled NO (FENO), a biomarker of airway inflammation.

274 ST2 predicts asthma and asthma with elevated exhaled NO (FeNO), compared to the commonly used Asthma

275 nitrite inhalation did not further increase exhaled NO concentration over inhaled nitrite alone in p

276 Exhaled NO levels were 21.3% higher in men compared with

277 Exhaled NO was measured at different flow-rates and Calv

278 Exhaled NO was measured, and alveolar concentration and

279 typic traits, sputum and blood eosinophilia, exhaled NO, serum cytokines and chemokines, total serum

280 penes and one ester were identified from the exhaled nose-space.

281 precolumn in the LC system and to collecting exhaled particles in an electret polymer filter.

282 Exhaled respiratory particles were collected in liquid a

283 ur findings revealed that deuterium-enriched exhaled semiheavy water, i.e., HD(16)O is a new marker o

284 oplets generated by infected persons through exhaling, talking, coughing and sneezing is a major driv

285 idgut into hemolymph, from which nicotine is exhaled through the spiracles as an antispider signal.

286 is intended, in part, to protect others from exhaled, virus-containing particles, few studies have ex

287 al-life clinical setting, the ability of the exhaled VOC analysis, using an electronic nose (eNose),

288 In a clinical setting, the analysis of the exhaled VOC profiles using an eNose could be used as a f

289 tive and negative likelihood ratios (LR) for exhaled VOC profiles were calculated; and publication bi

290 ly validated studies are needed to introduce exhaled VOC profiling in a clinical scenario.

291 Adding information on exhaled VOCs and possibly expression of inflammation gen

292 esults from the revised studies suggest that exhaled VOCs are promising biomarkers for asthma diagnos

293 matic search for published studies regarding exhaled VOCs in asthma diagnosis was conducted based on

294 Exhaled VOCs pattern from CRC patients is modified by ca

295 Information on exhaled VOCs significantly improved asthma prediction (A

296 ht relationship between tumor metabolism and exhaled VOCs.

297 A two-cluster exhaled volatile organic compound-based hierarchical mod

298 Analyses of exhaled volatile organic compounds (VOCs) have shown pro

299 assess the value and classification rate of exhaled volatile organic compounds (VOCs) in asthma diag

300 Biomarkers in exhaled breath condensate, exhaled volatile organic compounds (VOCs), gene expressi